STOCK TITAN

AtriCure (NASDAQ: ATRC) director exercises 25,000 options and sells 25,000 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AtriCure director Sven Wehrwein exercised 25,000 non-qualified stock options at an exercise price of $19.95 per share on July 28, 2026, converting them into 25,000 shares of common stock. The same day, he sold 25,000 shares at a weighted average price of $37.84 per share in multiple trades between $37.73 and $39.04. Following the exercise, no options remain outstanding under this specific grant.

Positive

  • None.

Negative

  • None.
Insider WEHRWEIN SVEN
Role Director
Sold 25,000 shs ($946K)
Approx. gross sale proceeds $946K
Approx. exercise cost $499K
Type Security Shares Price Value
Exercise Non-qualified Stock Option (right to buy) F2 25,000 $0.00 $0.00
Exercise Common Stock 25,000 $19.95 $499K
Sale Common Stock F1 25,000 $37.84 $946K
Holdings After Transaction: Non-qualified Stock Option (right to buy) — 0 shares (Direct); Common Stock — 40,518 shares (Direct)
Footnotes (2)
  1. F1. This transaction was executed in multiple trades at prices ranging from $37.73 to $39.04 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. F2. These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.
Options exercised 25,000 shares Non-qualified stock options exercised on 2026-07-28
Exercise price $19.95 per share Exercise price of non-qualified stock options
Shares sold 25,000 shares Common stock sold on 2026-07-28 following option exercise
Weighted average sale price $37.84 per share Weighted average price across multiple sale trades
Sale price range $37.73–$39.04 per share Range of prices for multiple trades in the sale transaction
Options remaining under grant 0 shares Non-qualified stock option grant balance after 25,000-share exercise
Option grant date November 11, 2016 Original grant date of the non-qualified stock options
Option expiration date November 11, 2026 Expiration date of the exercised non-qualified stock options
Non-qualified Stock Option financial
"Non-qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average sales price financial
"The price reported above reflects the weighted average sales price."
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
multiple trades financial
"This transaction was executed in multiple trades at prices ranging"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did AtriCure (ATRC) director Sven Wehrwein report in this Form 4?

Sven Wehrwein reported exercising 25,000 stock options at $19.95 per share and selling 25,000 common shares at a weighted average price of $37.84 on July 28, 2026.

How many AtriCure (ATRC) options did Sven Wehrwein exercise and at what price?

He exercised 25,000 non-qualified stock options at an exercise price of $19.95 per share. These options were originally granted in 2016 and fully vested under a four-year vesting schedule.

At what prices did AtriCure (ATRC) director Sven Wehrwein sell his shares?

He sold 25,000 common shares at a weighted average price of $37.84 per share, with individual trade prices ranging from $37.73 to $39.04, executed in multiple transactions.

Did Sven Wehrwein retain any AtriCure (ATRC) options from this specific grant?

No. After exercising 25,000 options associated with this grant, the reported remaining option balance under this non-qualified stock option grant is 0 shares, indicating it has been fully exercised.

What is the background of the AtriCure (ATRC) options Sven Wehrwein exercised?

The options were granted November 11, 2016, with 25% vesting after one year and the remaining 75% vesting monthly over the next three years, becoming fully exercisable before the reported 2026 exercise.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WEHRWEIN SVEN

(Last)(First)(Middle)
4877 EAST LAKE HARRIET PARKWAY

(Street)
MINNEAPOLIS MINNESOTA 55419

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/28/2026M25,000A$19.9565,518D
Common Stock07/28/2026S25,000D$37.84(1)40,518D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (right to buy)$19.9507/28/2026M25,00011/11/2017(2)11/11/2026Non-qualified Stock Option (right to buy)25,000$00D
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $37.73 to $39.04 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
2. These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.
Remarks:
/s/ Sven Wehrwein07/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)